Semaglutide for Weight Loss: How It Works, Results & Safety

Semaglutide is a once-weekly injectable GLP-1 receptor agonist that has become the reference drug of the modern weight-loss peptide class. In the STEP 1 trial, 1,961 adults with overweight or obesity received 2.4 mg of semaglutide weekly alongside lifestyle changes for 68 weeks and lost an average of 14.9% of their body weight, versus 2.4% on placebo. More than two-thirds reached at least 10% weight loss. It is the active ingredient in Ozempic, a medicine authorized in Canada since January 2018.

This guide explains what semaglutide is, how its mechanism works in the body, what the published clinical trials actually measured, the side-effect profile regulators flag, who should avoid it, and how it compares with tirzepatide and other GLP-1 peptides. Every claim below is tied to published trial data or Health Canada documents, cited in the References at the end. This article is educational information only — it is not medical advice. Speak with a qualified healthcare professional before considering any peptide or medication.

What Is Semaglutide?

Semaglutide is a synthetic analogue of human glucagon-like peptide-1 (GLP-1), a natural gut hormone released after eating. Developed by Novo Nordisk, it was first authorized for type 2 diabetes (as Ozempic) and later, in a higher 2.4 mg weekly dose, for chronic weight management. The molecule’s key engineering feature is a fatty-acid side chain that binds it to albumin in the blood, stretching its half-life to about one week — that is why a single subcutaneous injection covers the whole week.

It is important to separate the molecule from the brand names. Semaglutide is the drug; Ozempic and Wegovy are brand-name products containing it (an oral tablet form also exists for diabetes, but the weight-loss data comes from the injectable). When you see “Semaglutide” in our store, it refers to the same active peptide, not a different compound.

How Semaglutide Works: The GLP-1 Mechanism

GLP-1 receptors sit in several tissues that matter for body weight: the pancreas, the stomach, and — crucially — appetite-control circuits in the brain. As the classic review by Drucker and Nauck (2006) describes, activating these receptors does four things in parallel: it stimulates insulin release in a glucose-dependent way (only when blood sugar is high), it suppresses glucagon secretion, it slows gastric emptying so food stays in the stomach longer, and it signals satiety through central nervous system pathways.

The practical result is that people feel full sooner, stay full longer, and think about food less. This is not a stimulant effect — there is no increase in heart rate or thermogenesis. It is appetite suppression from both ends: a slower stomach and a quieter brain reward response to food. That dual action is why GLP-1 drugs produce meaningfully larger weight loss than most earlier appetite suppressants.

What the Clinical Trials Found: The STEP Program

The strongest evidence for semaglutide in weight management comes from the STEP (Semaglutide Treatment Effect in People with obesity) phase 3 program. The landmark study is STEP 1 (Wilding et al., published in the New England Journal of Medicine, 2021): 1,961 adults with overweight or obesity but without diabetes received either semaglutide 2.4 mg weekly or placebo for 68 weeks, both groups getting lifestyle counselling.

The headline results:

• Mean weight loss: −14.9% on semaglutide vs −2.4% on placebo (an estimated difference of −12.4 percentage points, about −15.3 kg vs −2.6 kg in absolute terms).
• Responders: 86.4% lost at least 5% of body weight (vs 31.5% on placebo), 69.1% lost at least 10% (vs 12.0%), and 50.5% lost at least 15% (vs 4.9%).
• Bonus effects: greater improvements in waist circumference, blood pressure, and cardiometabolic risk factors, plus better self-reported physical functioning.
• Side effects: nausea and diarrhea were the most common events, typically transient and mild-to-moderate, subsiding with time. About 4.5% of semaglutide users stopped treatment because of gastrointestinal events (vs 0.8% on placebo).

Subsequent STEP trials extended these findings to people with type 2 diabetes and to longer follow-up. The consistent message across the program: semaglutide 2.4 mg weekly produces sustained, clinically relevant weight loss as long as treatment continues, with a safety profile consistent with the broader GLP-1 drug class.

Semaglutide vs Tirzepatide: How Do They Compare?

Semaglutide was the first drug to define the modern standard for injectable weight-loss peptides, but it no longer stands alone. The most common comparison readers ask about is tirzepatide, a dual GIP/GLP-1 receptor agonist we cover in our dedicated Tirzepatide complete guide. Here is a straight comparison of what the pivotal trials reported — keeping in mind that trials with different populations cannot be compared head-to-head:

The practical takeaway: both drugs use the same basic GLP-1 mechanism, but tirzepatide adds GIP activity and, in its pivotal trial, showed a larger average weight reduction at the top dose. Semaglutide, by contrast, has the longest real-world track record of any GLP-1 peptide. For a three-way view that also covers retatrutide, see our Retatrutide vs. Tirzepatide comparison, and browse the full GLP-1 agonist peptides range to compare options.

Side Effects and Safety: What the Data Say

GLP-1 receptor agonists share a well-documented side-effect profile, dominated by the gut:

Common (mostly transient)

• Nausea — the most frequent complaint, typically peaking during the first weeks and easing as the dose stabilizes.
• Vomiting, diarrhea, and constipation — usually mild-to-moderate; in STEP 1 they typically subsided with time.
• Reduced appetite and early fullness — the intended mechanism, but it can overshoot, leading to under-eating and fatigue if protein intake drops too far.

The standard clinical strategy is slow, multi-week dose escalation: start low, increase gradually, and hold at a tolerated dose rather than chasing the maximum. Most tolerability problems come from increasing too fast, not from the drug itself.

Serious warnings to know

• Pancreatitis: cases have been reported with the GLP-1 class. Sudden severe upper-abdominal pain (with or without vomiting) is a stop-and-see-a-doctor symptom.
• Thyroid C-cell tumors: animal studies showed thyroid tumors at high exposures; prescription labelling carries this warning and people with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome are told to avoid the drug.
• Gallbladder disease: rapid weight loss itself raises gallstone risk — worth flagging to your clinician.
• Pregnancy and breastfeeding: not recommended; reliable contraception is advised during use.

Harm-Reduction Notes: Using Weight-Loss Peptides Responsibly

This section is for readers researching these peptides outside of a prescription pathway. We are not endorsing unsupervised use — but facts reduce harm:

• Get bloodwork first and periodically: baseline HbA1c, fasting glucose, lipids, liver and kidney markers, and thyroid panel. Recheck at least every few months; GLP-1 drugs alter glycemia, and you want numbers, not guesses.
• Sterile technique is non-negotiable: bacteriostatic water for reconstitution, single-use sterile needles, alcohol-swabbed vials and injection sites, and refrigerator storage of reconstituted peptides.
• Eat enough protein and keep exercising: rapid weight loss without resistance training costs muscle. Aim for high-protein meals and 2–3 resistance sessions weekly; severe nausea is a signal to lower the dose, not to starve through it.
• Know the red flags: persistent vomiting, signs of dehydration, upper-abdominal pain, or a lump in the neck warrant prompt medical attention.
• Plan the exit: trial follow-up data show weight tends to return after stopping. Think of maintenance — diet, activity, and follow-up bloodwork — as part of the plan from day one, not an afterthought.

Semaglutide in Canada

Ozempic (semaglutide) received its Health Canada Notice of Compliance in January 2018 for type 2 diabetes, making it one of the longest-authorized GLP-1 medicines in the country. It is a prescription-only medicine in Canada — it cannot be legally dispensed without one, and pharmacy-grade product comes with a full product monograph describing the approved uses, contraindications, and interactions.

Supply shortages and the weight-loss demand wave have complicated access in recent years, and generic semaglutide options began entering the Canadian market in 2026. Anyone offered “no-prescription” brand Ozempic should be cautious: counterfeit GLP-1 products are a documented global problem, and fake pens may contain no active ingredient — or the wrong one.

Frequently Asked Questions

Does semaglutide work without diet and exercise?

Every pivotal trial paired semaglutide with lifestyle counselling. The −14.9% result in STEP 1 reflects the drug plus diet and activity changes; nobody tested the drug against doing nothing. Treat lifestyle as part of the intervention, not an optional extra.

How fast will I see results?

Weight loss is gradual: in STEP 1 the average curve kept descending through the full 68 weeks without a plateau at the end. Most people notice appetite changes within the first weeks, but the clinically meaningful fat-loss phase plays out over months. Anyone promising dramatic results in days is selling, not informing.

Is Ozempic the same as semaglutide?

Yes — semaglutide is the molecule, Ozempic is a brand name. The diabetes-approved weekly dose and the higher weight-management dose contain the same active peptide; only the target dose and labelling differ.

What happens when you stop taking semaglutide?

Follow-up extensions of the STEP trials show that weight loss is largely regained within about a year of stopping, along with a reversal of cardiometabolic gains. This is why guidelines frame GLP-1 therapy as long-term treatment of a chronic condition rather than a one-off course — and why a maintenance plan matters before the first dose.

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183 (STEP 1, PMID 33567185).
2. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-1705. DOI: 10.1016/S0140-6736(06)69705-5 (GLP-1 mechanism review).
3. Health Canada. Regulatory Decision Summary — Ozempic (semaglutide). Decision 2023-08-04. Available at: Health Canada Drug and Health Products Portal. Ozempic authorized in Canada January 2018 per Novo Nordisk company announcement.

Looking for the full range of weight-management compounds covered here? See our shop range — and remember, education first: this content exists to inform, not to replace medical guidance.